MedTrace Logo

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

NCT06468358 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2025-09-11

No results posted yet for this study

Summary

This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

LB1410

anti-PD-1/TIM3 bispecific antibody

DRUG

LB4330

anti-claudin18.2/IL-10 fusion protein

Sponsors & Collaborators

  • Shanghai East Hospital

    collaborator OTHER

  • L & L Bio Co., Ltd., Ningbo, China

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou · Shanghai East Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2026-12-30
Completion
2027-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06468358 on ClinicalTrials.gov